Nonhormonal menopause treatments: options and monitoring to discuss

Start with the symptom rather than the newest drug

Hot flashes and night sweats are often called vasomotor symptoms. A medicine approved for those symptoms should not automatically be expected to address vaginal discomfort, a mood disorder or every cause of poor sleep. Tell the clinician which problem is most disruptive and what you have already tried.

Also explain why you are considering nonhormonal treatment. Personal preference, a previous side effect and a medical reason to avoid estrogen may lead to different conversations. If you have a history of cancer or are taking cancer treatment, coordination with the relevant specialist is especially important.

Prescription options include more than one drug class

FDA-approved nonhormonal medicines for menopausal hot flashes include the specific paroxetine product Brisdelle, fezolinetant sold as Veozah and elinzanetant sold as Lynkuet. These are examples to discuss, not a claim that each is suitable for you or stocked by every online service. FDA approval does not make their risks or monitoring identical.

The FDA approved Lynkuet in October 2025 for moderate to severe vasomotor symptoms due to menopause. Older articles describing only one newer nonhormonal prescription can therefore be incomplete. Ask the clinician to use current prescribing information and confirm the actual pharmacy availability and coverage for any proposed product.

Liver monitoring is part of the treatment decision

Veozah carries an FDA boxed warning about rare serious liver injury. The FDA calls for liver tests before treatment, monthly during the first three months, and at months six and nine. Ask who orders and reviews the tests, what they cost and how the results affect continued prescribing.

The FDA advises stopping Veozah immediately and contacting the prescriber if signs of liver injury occur, such as jaundice, dark urine, unusual itching or new marked fatigue. Read the full patient information for the complete warning signs. A general promise of online support is not a replacement for knowing how to reach the clinical team.

Lynkuet has different label requirements, including liver testing before treatment and at three months. Its August 2026 US label also warns about drowsiness and daytime impairment, pregnancy loss and a risk of seizure. Tell the clinician about all medicines and supplements; interaction checks and reproductive history remain relevant even though the treatment is nonhormonal.

Understand what off-label means

Clinicians may discuss other medicines, such as gabapentin or certain antidepressants, for hot flashes. An off-label use means the specific use is outside the drug’s FDA-approved indication. It does not by itself settle whether the choice is appropriate, but the clinician should explain the evidence, tradeoffs and follow-up.

Do not assume a different paroxetine brand, dose or formulation has the same approved indication as Brisdelle. Nor should a website’s broad medication menu be read as a list of equally preferred options. Ask why the proposed choice fits your symptom, other treatments and health history.

Plan for the symptoms a prescription does not address

Ask whether a separate approach is needed for vaginal discomfort or persistent insomnia. Our local versus systemic treatment guide and sleep guide help organize those questions. Any suggested behavioral treatment or nonprescription product deserves its own explanation of evidence and purpose.

The online nonhormonal-care shortlist identifies services that publish relevant options, while distinguishing our promotional placement. Before paying, confirm that the clinician can manage the necessary monitoring and referrals. Leave the appointment knowing the target symptom, the next review date and what would require earlier contact.